USFDA concludes PAI at Hyderabad facility of Granules India’s arm

02 Aug 2025 Evaluate

The U.S. Food & Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) at Granules India’s wholly owned Indian subsidiary -- M/s Granules Life Sciences’ Hyderabad facility. The USFDA has conducted inspection from July 28, 2025 to August 01, 2025. The said facility has received one 483 observation, which is procedural in nature.

The Company will respond to this observation within the stipulated time. Granules Life Sciences is engaged in the manufacturing of PFI & Finished Dosages.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages.


Granules India Share Price

563.60 -2.95 (-0.52%)
05-Dec-2025 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1521.50
Zydus Lifesciences 933.10
Lupin 2089.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×